title: Iconix Biosciences, Inc.
abstract: Iconix Biosciences has developed leading products and services that apply novel and proprietary genomic technologies to profile candidate drug compounds in early discovery through to preclinical development, leading to a better understanding of candidate drugs in a faster, more cost-effective manner. The toxicology community is embracing this approach to increase the accuracy, sensitivity and speed of toxicity testing. Changing this paradigm will significantly impact the failure rate of late-stage preclinical compounds and provide a compelling return on investment. Through strategic growth and research, the company has identified the factors and is creating the environment that will lead to a 'tipping point' in the pharmaceutical and biotechnology industries, such that toxicogenomics becomes a standard practice in the drug discovery and development process.
authors: Iconix Biosciences, Inc., Molecular and Investigative Toxicology, 325 E Middlefield Road, Mountain View, CA 94043, USA. mfielden@iconixbiosciences.com
authors: Mark R
authors: MR
authors: Fielden
authors: Donald N
authors: DN
authors: Halbert
mesh_terms: D000818:Animals; D004345:Drug Industry / Q000379:methods* / Q000639:trends; D023281:Genomics / Q000379:methods / Q000639:trends; D006801:Humans; D013678:Technology, Pharmaceutical / Q000379:methods / Q000639:trends; D043922:Toxicogenetics / Q000379:methods* / Q000639:trends